Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of standard dose or high dose sensitivity. This modification seems to have favored an inappropriate overprescription of Meropenem (the only antibiotic made at standard dose) in Pseudomonas infections sensitive to other beta-lactams. In June 2021, it was therefore decided to mask sensitivity to carbapenems by default in the rendering of Pseudomonas antibiograms when the strain was sensitive to a narrower spectrum beta-lactam (restricted antibiogram). The aim of this study is to evaluate the impact of these changes in the antibiogram on antibiotic prescriptions.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Major subject (≥18 years old)

• Subject with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022

• Subject not opposing the reuse of their data for the purposes of this research.

Locations
Other Locations
France
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
RECRUITING
Strasbourg
Contact Information
Primary
Yvon RUCH, MD
yvon.ruch@chru-strasbourg.fr
33 3 69 55 12 19
Time Frame
Start Date: 2023-03-01
Estimated Completion Date: 2024-03-13
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Strasbourg, France

This content was sourced from clinicaltrials.gov